A phase Ib/II randomized study of RO4929097, a gamma-secretase or notch inhibitor with or without vismodegib, a hedgehog inhibitor, in advanced sarcoma Journal Article
| Authors: | Gounder, M. M.; Rosenbaum, E.; Wu, N.; Dickson, M. A.; Sheikh, T. N.; D'Angelo, S. P.; Chi, P.; Keohan, M. L.; Erinjeri, J. P.; Antonescu, C. R.; Agaram, N.; Hameed, M. R.; Martindale, M.; Lefkowitz, R. A.; Crago, A. M.; Singer, S.; Tap, W. D.; Takebe, N.; Qin, L. X.; Schwartz, G. K. |
| Article Title: | A phase Ib/II randomized study of RO4929097, a gamma-secretase or notch inhibitor with or without vismodegib, a hedgehog inhibitor, in advanced sarcoma |
| Abstract: | Purpose: Because the Hedgehog and Notch pathways are often overexpressed in mesenchymal malignancies, we evaluated the efficacy of concurrent inhibition of Notch and Hedgehog signaling using the gamma-secretase inhibitor (GSI) RO4929097 and the smoothened antagonist vismodegib in unresectable or metastatic sarcoma. Patients and Methods: In this investigator-initiated trial, phase Ib used standard 3+3 dose escalation in which patients first received vismodegib once daily for 21 days, followed by the combination of RO4929097 concurrently with vismodegib in 21-day cycles. In phase II, patients were randomized to RO4929097 alone or in combination with vismodegib. Results: Nine patients were treated in phase Ib with no doselimiting toxicities. RO4929097 at 15 mg daily in combination with 150 mg daily of vismodegib was declared the recommended phase II dose. Most adverse events were grade ≤ 2. In phase II (closed early due to discontinuation of RO4929097 evaluation), 34 patients were randomized to RO4929097 alone and 33 to RO4929097 plus vismodegib. RO4929097 did not interfere with the steady-state concentration of vismodegib, while vismodegib reduced the plasma concentration of RO492909. No patients had an objective response. Neither progression-free nor overall survival differed significantly between treatment arms. Paired tumor biopsies from a subset of patients demonstrated inhibition of cleaved Notch. Conclusions: The combination of RO4929097 plus vismodegib was generally well tolerated. Although accrual to this study was not completed, vismodegib did not meaningfully enhance the clinical efficacy of RO4929097 in an unplanned analysis. GSIs and GSIs plus vismodegib can inhibit intratumoral Notch and downstream phosphorylated Akt signaling. ©2022 American Association for Cancer Research. |
| Keywords: | controlled study; clinical trial; pyridines; randomized controlled trial; sonic hedgehog protein; hedgehog proteins; sarcoma; phase 1 clinical trial; benzazepines; anilides; amyloid precursor protein secretases; pyridine derivative; anilide; secretase; vismodegib; fluorocarbons; fluorocarbon; humans; human; 2,2-dimethyl-n-(6-oxo-6,7-dihydro-5h-dibenzo(b,d)azepin-7-yl)-n'-(2,2,3,3,3-pentafluoropropyl)malonamide; benzazepine derivative |
| Journal Title: | Clinical Cancer Research |
| Volume: | 28 |
| Issue: | 8 |
| ISSN: | 1078-0432 |
| Publisher: | American Association for Cancer Research |
| Date Published: | 2022-04-15 |
| Start Page: | 1586 |
| End Page: | 1594 |
| Language: | English |
| DOI: | 10.1158/1078-0432.Ccr-21-3874 |
| PUBMED: | 35110418 |
| PROVIDER: | scopus |
| PMCID: | PMC9187109 |
| DOI/URL: | |
| Notes: | Article -- Export Date: 2 May 2022 -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
Related MSK Work